News | July 22, 2023
Merck receives positive European Union CHMP opinion for Gefapixant
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
The strategic acquisition demonstrates the company’s commitment to increasing OTC consumer convenience in eye care
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Subscribe To Our Newsletter & Stay Updated
